DEST.L Regulatory News (DEST)

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri Martina as Chief Medical Officer

Brighton, United Kingdom - 3rd May 2022 - Destiny Pharma plc (AIM:DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces the appointment of Dr. Yuri Martina as Chief Medical Officer (CMO).

Yuri brings to Destiny Pharma more than 20 years' experience and an extensive record of excellence in clinical development and successful interactions at the highest levels with key regulatory, industry and government stakeholders including the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and the Japanese Pharmaceutical and Medical Device Agency (PMDA).

Most recently, Yuri was Senior Vice President Development and deputy CMO at Grünenthal Group where he was a key member of the Global R&D Leadership and the Global Commercial Leadership Teams. Yuri has been responsible for advancing the Grünenthal Group R&D pipeline, including two phase 3 assets, two phase 2 assets and several early and pre-clinical assets. Yuri has also been a key member and driver in several in-licensing and out-licensing activities and in the completion of the acquisition of Mestex AG.

From 2014 to 2017, Yuri was Vice President Development and Clinical Operations in Shionogi Europe, where he was a key contributor to the approval of Mulpeo (previously Lusutrombopag) and Cefiderocol.

Throughout his career, Yuri has gained a deep insight into global markets, working in Europe, the US, Middle East and Asia and has contributed to more than ten submissions for Marketing Authorisation Applications (MAA) to the EMA and New Drug Applications (NDA) to the FDA.

Yuri is a Medical Doctor by background, and also holds a PhD in Genetics and Molecular Biology, an MBA and a Master's in Project Management. Yuri is also a fellow member of the Royal Society of Medicine.

Neil Clark, Chief Executive Officer, Destiny Pharma said: "Yuri is an important new member of our team, as he brings the right skill sets to drive the strategy, direction and execution of the Company's Phase 3 clinical development plans as we move towards the next phase of our growth."

Dr. Yuri Martina, Chief Medical Officer, Destiny Pharma, said: "I very much look forward to being an integral part of Destiny Pharma's leadership management team at such a pivotal moment in the Company's history. I feel privileged to be able to contribute to progressing the pipeline of our unique late-stage clinical assets addressing patients' unmet needs and delivering on the Company's strategy to build a world-leading infection prevention company."

ENDS

For further information, please contact:

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

+44 (0)1273 704 440 

pressoffice@destinypharma.com 

Optimum Strategic Communications 

Mary Clark / Manel Mateus /Vici Rabbetts

+44 (0) 208 078 4357

DestinyPharma@optimumcomms.com 

finnCap Ltd (Nominated Advisor and Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

MC Services AG 

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit www.destinypharma.com